Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Virilism
ADR ID BADD_A04583
ADR Hierarchy
05      Endocrine disorders
05.05      Endocrine disorders of gonadal function
05.05.01      Female gonadal function disorders
05.05.01.001      Virilism
21      Reproductive system and breast disorders
21.10      Reproductive tract disorders NEC
21.10.04      Gender disorders
21.10.04.001      Virilism
Description Development of male secondary SEX CHARACTERISTICS in the FEMALE. It is due to the effects of androgenic metabolites of precursors from endogenous or exogenous sources, such as ADRENAL GLANDS or therapeutic drugs. [MeSH]
MedDRA Code 10047486
MeSH ID D014770; D014770; D014770
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Androgen excess effect | Hermaphroditism female | Masculinisation | Masculinization | Virilism | Virilization | Virilisation | Androgenization
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00107Aminoglutethimide--
BADD_D00623Dexamethasone0.002403%
BADD_D00934Fluoxymesterone--
BADD_D01167Interferon alfa-2b--
BADD_D01261Leuprolide monoacetate--
BADD_D01438Methyltestosterone--
BADD_D01473Minoxidil--
BADD_D01530Nandrolone decanoate--
BADD_D01585Norethindrone--
BADD_D01634Oxandrolone--
BADD_D01835Pregabalin--
BADD_D01933Ribavirin--
BADD_D02170Testosterone0.003266%
BADD_D02172Testosterone enanthate--
The 1th Page    1    Total 1 Pages